
Neuroene Therapeutics LLC Profile last edited on: 9/6/2019
CAGE: 7EGQ1
UEI: FE9HTJ2TLGY5
Business Identifier: Novel Vitamin K-based therapeutics for neurological disorders Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
645 Meeting Street Suite 10
Charleston, SC 29403
Charleston, SC 29403
Location: Single
Congr. District: 06
County: Charleston
Congr. District: 06
County: Charleston
Public Profile
Neuroene Therapeutics is organized around development of new therapeutics for difficult-to-treat neurological diseases: epilepsy, Parkinson and Mitochhrondrial disease. Anchored in collaborative research between Medical University of South Carolina and the firm's principals, the firm is working on a novel Vitamin K based therapeutics that target new mechanisms and are safe, specific, and different to current drugs on the market for the trageted diseases noted. Himan body organs need an active form of Vitamin K in order to be healthy. However, the form of Vitamin K that is obtained from a person's diet needs to be further processed, to produce the active form for the proper function and health of the organ. The modified form of Vitamin K which Neuroene principals are developing doesnt need to be processed because it is a direct substitute for the active form that goes directly to the organ where it is needed.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2024 | 2 | NIH | $598,010 | |
Project Title: A Vitamin K analog countermeasure for organophosphate poisoning | ||||
2019 | 2 | NIH | $1,724,722 | |
Project Title: Novel mechanism for the treatment of epilepsy: New Vitamin K analogs target energetics and have low toxicity due to excellent specificity and low dose requirements compared to current therapies |
Key People / Management
C James Chou -- Founder and CEO
Sherine S Chan
Richard Himes -- CSO
Sherine S Chan
Richard Himes -- CSO
Company News
There are no news available.